Novartis (NVS) Stock Analysis: AI Score & Alternative Data
NVS alt-data: web traffic climbing, job postings lagging
Is Novartis a buy right now? The alternative data leans no. This NVS stock analysis is built on the 25+ alternative data signals AltIndex tracks on Novartis every day — hiring, web traffic, sentiment, social reach — rolled into an AI Score of 38/100: a Sell. The stock trades at $137.48 with a $304B market cap.
The 90-day pressure points: job postings down 7.6% to 924 open roles, and sentiment down 18.0% to 82/100. There are bright spots — web traffic up 34.4% to 1.3M monthly visits, and 70% of employees are positive on the business outlook — but not enough to offset the broader weakness.
NVS’s broader alt-data profile also covers headcount (87K employees, according to LinkedIn), quarterly revenue ($14.4B), Facebook followers (425K), and Reddit mentions (14 a day). Every signal links to its own page with full history, the NVS technical analysis covers RSI, moving averages, and support and resistance, and the full table of everything AltIndex tracks on NVS is just below.
Novartis AI Stock Analysis
Novartis is a global healthcare company based in Switzerland that provides solutions to address the evolving needs of patients worldwide. The company's operations involve the research, development, manufacturing, and marketing of pharmaceuticals and medical devices.
Analysis generated September 1, 2026.
Recent Novartis Stock Alerts
|
Novartis | September 8 Price is down by -12.5% in the last 24h. |
|
Novartis | September 1 Price is up by 6.6% in the last 24h. |
|
Novartis | August 10 Web Traffic is down by 59.8% over the last month. |
|
Novartis | August 1 Over the past few months, there has been a noticeable downward trend in Instagram Followers. |
Novartis Alternative Data
| Alternative Data | Value | 3m Change | Trend |
|---|---|---|---|
| Webpage Traffic | 1.3M | 34.4% | |
| Job Posts | 924 | 7.6% | |
| LinkedIn Employees | 87K | 4.0% | |
| Employee Recommend | 81 | 1.3% | |
| Business Outlook | 70 | 1.4% | |
| Lobbying Cost | $353K | 0% | |
| Sentiment | 82 | 18.0% | |
| Reddit Mentions | 14 | N/A | |
| X Mentions | 20 | 122.2% | |
| Stocktwits Mentions | 100 | 1,900.0% | |
| News Mentions | 39 | 200.0% | |
| Stocktwits Subscribers | 7K | 3.3% | |
| 4chan Mentions | 0 | N/A | |
| X Followers | 287K | 0% | |
| Instagram Followers | 149K | 0% | |
| Youtube Subscribers | 57K | 0% | |
| Facebook Followers | 425K | 0% | |
| Facebook Engagement | 4K | 91.7% |
About Novartis (NVS)
Novartis AG develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The firm sells its products globally, with the United States representing close to one third of total revenue.
| Price | $137.48 |
| Target Price | $387.74 |
| Volume | 63,420,177 |
| Market Cap | $304B |
| Year Range | $118 – $164 |
| Dividend Yield | 0% |
| PE Ratio | 24.2 |
| Analyst Rating | 38% buy |
| Industry | Biotechnology |
Latest Novartis News
View more → |
European shares dip slightly on inflation concerns and Novartis weighs on drugmakersSeptember 8 - The Irish Times |
 |
Amgen Falls 10% as Novartis Trial Failure Clouds a Cholesterol Drug Class; NVS Stock Drops 14%September 8 - 24/7 Wall St. |
 |
Novartis’s failed trial for cholesterol drug leads to broad biopharma stock selloffSeptember 8 - Biztoc.com |
|
How Novartis And Ionis' High-Profile Failure Reverberated Through BiopharmaSeptember 8 - Biztoc.com |
 |
Novartis Stock Falls 12% on Its Third Trial Setback In a WeekSeptember 8 - Biztoc.com |
See Novartis’s complete price and AI Score history
Sign up to unlock 1-year and all-time charts for NVS, plus 25+ alternative data signals, AI Scores, and real-time alerts.
Get Started for FREENovartis Earnings & Financial Performance
View all earnings →Novartis Insider Trading Activity
View all →| No recent insider transactions on file. |
Novartis Congress Trading
View all →| Politician | Filing Date | Type | Size |
|---|---|---|---|
| Lisa McClain |
Oct 23, 25 | Sell | $8K+ |
| Lisa McClain |
Oct 22, 25 | Buy | $8K+ |
| Lisa McClain |
Aug 13, 25 | Buy | $8K+ |
| Lisa McClain |
Aug 13, 25 | Buy | $8K+ |
| Lisa McClain |
Aug 13, 25 | Buy | $8K+ |
Stocks Similar to Novartis
See all →| Company | Price | Market Cap | AI Score | |
|---|---|---|---|---|
 |
AmgenAMGN |
$391.27 0.5% | $236B | 50 |
 |
Thermo Fisher ScientificTMO |
$605.69 0.4% | $227B | 66 |
 |
Gilead SciencesGILD |
$145.65 0.7% | $187B | 61 |
 |
Vertex PharmaceuticalsVRTX |
$521.12 1.5% | $138B | 68 |
 |
RegeneronREGN |
$807.65 0.3% | $85B | 56 |
Explore Novartis Data
Frequently Asked Questions: Novartis (NVS)
Novartis has an AltIndex AI Score of 38/100 (Sell). The score reflects negative alternative data signals. All investments carry risk.
38/100. The AI Score combines 25+ alternative data signals including job postings, employee sentiment, social media, web traffic, and financials. Scores above 60 = buy, 40–59 = hold, below 40 = sell. Updated daily.
Currently, the price of one share of Novartis (NVS) stock is $137.48 with a market cap of $304B.
As of today, Novartis’s PE (Price to Earnings) ratio is 24.2.
View the latest Novartis insider transactions to see recent buying and selling activity by company executives and directors.
Check the Novartis congress trading page for the latest disclosed trades by U.S. senators and representatives.
AltIndex tracks 25+ signals including job postings, web traffic, employee sentiment, Reddit mentions, Stocktwits activity, insider transactions, congressional trades, Google Trends, app downloads, and more.
The NVS stock price chart above shows Novartis’s performance over time alongside its AI Score. Investors can identify patterns, trends, and potential support or resistance levels. View the full Novartis technical analysis for RSI, moving averages, and more.
See the stocks similar to Novartis section on this page for companies in the same industry ranked by market cap and AI Score.
